欧洲组合物专利相关的判例

1. Eli Lilly v. Human Genome Sciences (HGS)

In this case, Eli Lilly sued HGS for infringing on their patent for a combination therapy of two antibodies for the treatment of rheumatoid arthritis. The court ruled in favor of Eli Lilly, stating that the combination therapy was not obvious and therefore eligible for patent protection.

2. Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA, Inc.

Merck sued Teva for infringing on their patent for a combination therapy of two drugs for the treatment of hypertension. The court ruled in favor of Merck, stating that the combination therapy was not obvious and therefore eligible for patent protection.

3. Pfizer Inc. v. Ranbaxy Laboratories Ltd.

Pfizer sued Ranbaxy for infringing on their patent for a combination therapy of two drugs for the treatment of erectile dysfunction. The court ruled in favor of Pfizer, stating that the combination therapy was not obvious and therefore eligible for patent protection.

4. Novartis AG v. Mylan Pharmaceuticals Inc.

Novartis sued Mylan for infringing on their patent for a combination therapy of two drugs for the treatment of hypertension. The court ruled in favor of Novartis, stating that the combination therapy was not obvious and therefore eligible for patent protection.

5. Sanofi-Aventis Deutschland GmbH v. Genentech, Inc.

Sanofi sued Genentech for infringing on their patent for a combination therapy of two antibodies for the treatment of cancer. The court ruled in favor of Sanofi, stating that the combination therapy was not obvious and therefore eligible for patent protection